Cargando…
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
In Brief Sodium–glucose cotransporter 2 (SGLT2) inhibitors and incretin-based therapies (dipeptidyl peptidase-4 [DPP-4] inhibitors and glucagon-like peptide-1 [GLP-1] receptor agonists) are widely used to treat patients with type 2 diabetes. In clinical and real-world studies, canagliflozin, an SGLT...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510927/ https://www.ncbi.nlm.nih.gov/pubmed/28761216 http://dx.doi.org/10.2337/cd16-0063 |